Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQC2731 in poorly controlled severe asthma
NCT05472324Phase 2Completed
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Sep 2022
- Primary completion
- Mar 2025
- Modality
- IgG Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of bosakitug in severe asthma, sponsored by Chia Tai-Tianqing Pharmaceutical Group. Started Sep 2022; status: completed.
02
Drugs
bosakitug
03
Conditions
severe asthma
Beyond the preview
Go deeper on NCT05472324.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05472324.